cell signaling technology hsp90 Search Results


rabbit mab anti hsp90  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc rabbit mab anti hsp90
Rabbit Mab Anti Hsp90, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+hsp90/HSP90+Rabbit+mAb/pmc12786736-101-49-53
Average 97 stars, based on 1 article reviews
rabbit mab anti hsp90 - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
hsp90  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc hsp90
Targeting PI3K-Akt-mTOR signaling. (A) U251 and T98G cells were pretreated with rapamycin (RPM) plus TMZ for 24 h and subjected to western blot analysis using the indicated antibodies. Pretreatment with rapamycin (100 nM) plus TMZ (25 μM) did not have a synergistic radiosensitizing effect compared to TMZ alone treatment on U251 and T98G cells. (B) U251 and T98G cells were pretreated with a dual inhibitor of class I PI3K and mTOR signaling, PI103 (0.4 μM), and TMZ (25 μM) for 24 h. PI103 effectively enhanced the radiosensitizing effect of TMZ in both U251 and T98G cells. (C) U251 and T98G cells were pretreated with the <t>HSP90</t> inhibitor 17-DMAG (25nM) and TMZ (25 μM) for 24 h. 17-DMAG enhanced the radiosensitizing effect of TMZ in U251 and T98G cells. (D) U251 and T98G cells were pretreated with TMZ (25 μM) and LBH589 (20 nM) for 24 h. LBH589 effectively potentiated the radiosensitizing effect of TMZ. Points on survival curves represent mean surviving fractions from minimum three experiments performed in triplicate.
Hsp90, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+hsp90/HSP90+Antibody/pmc03910677-58-29-39
Average 96 stars, based on 1 article reviews
hsp90 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
hsp90 e289  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc hsp90 e289
(Ruxolitinib + afatinib) rapidly reduces CDC37 Serine 13 phosphorylation and after 6 h CDC37 total expression . (A,B) SUM149 cells were treated with vehicle control or with (ruxolitinib + afatinib) for 2 h or for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed: (A) at 10× magnification to detect the total expression and phosphorylation levels of CDC37 and CDC37 Serine 13, respectively; (B) at 60× magnification the total expression of <t>HSP90</t> and the total expression of CDC37, and the co-localization of the two proteins ( n = 3 ± SEM) * p < 0.05 greater decline than CDC37 protein expression. (C) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total expression of MCL-1 and BCL-XL ( n = 3 ± SEM) * p < 0.05 lower decline than vehicle control. (D) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 24 h. Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification ( n = 3 ± SEM) * p < 0.05 greater survival than individual expression of chaperones.
Hsp90 E289, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+hsp90/HSP90+(E289)+Antibody/pmc04904019-94-3-5
Average 93 stars, based on 1 article reviews
hsp90 e289 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
hsp90 hrp  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc hsp90 hrp
(Ruxolitinib + afatinib) rapidly reduces CDC37 Serine 13 phosphorylation and after 6 h CDC37 total expression . (A,B) SUM149 cells were treated with vehicle control or with (ruxolitinib + afatinib) for 2 h or for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed: (A) at 10× magnification to detect the total expression and phosphorylation levels of CDC37 and CDC37 Serine 13, respectively; (B) at 60× magnification the total expression of <t>HSP90</t> and the total expression of CDC37, and the co-localization of the two proteins ( n = 3 ± SEM) * p < 0.05 greater decline than CDC37 protein expression. (C) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total expression of MCL-1 and BCL-XL ( n = 3 ± SEM) * p < 0.05 lower decline than vehicle control. (D) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 24 h. Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification ( n = 3 ± SEM) * p < 0.05 greater survival than individual expression of chaperones.
Hsp90 Hrp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+hsp90/HSP90+Rabbit+mAb/bio_rxiv__2025__05__06__652547-292-12-13
Average 95 stars, based on 1 article reviews
hsp90 hrp - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
hrp  (Cell Signaling Technology Inc)
92
Cell Signaling Technology Inc hrp
(Ruxolitinib + afatinib) rapidly reduces CDC37 Serine 13 phosphorylation and after 6 h CDC37 total expression . (A,B) SUM149 cells were treated with vehicle control or with (ruxolitinib + afatinib) for 2 h or for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed: (A) at 10× magnification to detect the total expression and phosphorylation levels of CDC37 and CDC37 Serine 13, respectively; (B) at 60× magnification the total expression of <t>HSP90</t> and the total expression of CDC37, and the co-localization of the two proteins ( n = 3 ± SEM) * p < 0.05 greater decline than CDC37 protein expression. (C) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total expression of MCL-1 and BCL-XL ( n = 3 ± SEM) * p < 0.05 lower decline than vehicle control. (D) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 24 h. Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification ( n = 3 ± SEM) * p < 0.05 greater survival than individual expression of chaperones.
Hrp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signaling+technology+hsp90/HSP90+Rabbit+mAb/10__12659_slash_msm__923533-59-19-25
Average 92 stars, based on 1 article reviews
hrp - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

Image Search Results


Targeting PI3K-Akt-mTOR signaling. (A) U251 and T98G cells were pretreated with rapamycin (RPM) plus TMZ for 24 h and subjected to western blot analysis using the indicated antibodies. Pretreatment with rapamycin (100 nM) plus TMZ (25 μM) did not have a synergistic radiosensitizing effect compared to TMZ alone treatment on U251 and T98G cells. (B) U251 and T98G cells were pretreated with a dual inhibitor of class I PI3K and mTOR signaling, PI103 (0.4 μM), and TMZ (25 μM) for 24 h. PI103 effectively enhanced the radiosensitizing effect of TMZ in both U251 and T98G cells. (C) U251 and T98G cells were pretreated with the HSP90 inhibitor 17-DMAG (25nM) and TMZ (25 μM) for 24 h. 17-DMAG enhanced the radiosensitizing effect of TMZ in U251 and T98G cells. (D) U251 and T98G cells were pretreated with TMZ (25 μM) and LBH589 (20 nM) for 24 h. LBH589 effectively potentiated the radiosensitizing effect of TMZ. Points on survival curves represent mean surviving fractions from minimum three experiments performed in triplicate.

Journal: BMC Cancer

Article Title: Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases

doi: 10.1186/1471-2407-14-17

Figure Lengend Snippet: Targeting PI3K-Akt-mTOR signaling. (A) U251 and T98G cells were pretreated with rapamycin (RPM) plus TMZ for 24 h and subjected to western blot analysis using the indicated antibodies. Pretreatment with rapamycin (100 nM) plus TMZ (25 μM) did not have a synergistic radiosensitizing effect compared to TMZ alone treatment on U251 and T98G cells. (B) U251 and T98G cells were pretreated with a dual inhibitor of class I PI3K and mTOR signaling, PI103 (0.4 μM), and TMZ (25 μM) for 24 h. PI103 effectively enhanced the radiosensitizing effect of TMZ in both U251 and T98G cells. (C) U251 and T98G cells were pretreated with the HSP90 inhibitor 17-DMAG (25nM) and TMZ (25 μM) for 24 h. 17-DMAG enhanced the radiosensitizing effect of TMZ in U251 and T98G cells. (D) U251 and T98G cells were pretreated with TMZ (25 μM) and LBH589 (20 nM) for 24 h. LBH589 effectively potentiated the radiosensitizing effect of TMZ. Points on survival curves represent mean surviving fractions from minimum three experiments performed in triplicate.

Article Snippet: Membranes were blocked in PBS containing 0.1% Tween 20 and 5% powdered milk and probed with primary antibody directed against p-EGFR (Tyr1068), p-Akt (Ser473), p-ERK (Tyr202/204), p-p70S6K (Thr421/Ser424), HSP70, HSP90, DNA-PKs (Thr2609), Rad51, caspase-3, LC3, MMP-2, E-cadherin, and EphA2 (Cell Signaling Technology, Inc.) at 1:1000 dilutions.

Techniques: Western Blot

Impairment of DNA damage repair following irradiation. (A) U251 cells were pretreated with the indicated inhibitors plus TMZ before assessment of γH2AX foci formation. Mock-treated control cells were analyzed 6 h after irradiation with 6 Gy. Pretreatment of U251 cells with the dual inhibitor PI103, the HSP90 inhibitor 17-DMAG, or the HDAC inhibitor LBH589 plus TMZ caused marked prolongation of radiation-induced γH2AX foci formation 6 h after 6Gy irradiation. (B) Pretreatment of U251 cells with TMZ combined with PI103, 17-DMAG, or LBH589 attenuated p-DNA-PK expression.

Journal: BMC Cancer

Article Title: Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases

doi: 10.1186/1471-2407-14-17

Figure Lengend Snippet: Impairment of DNA damage repair following irradiation. (A) U251 cells were pretreated with the indicated inhibitors plus TMZ before assessment of γH2AX foci formation. Mock-treated control cells were analyzed 6 h after irradiation with 6 Gy. Pretreatment of U251 cells with the dual inhibitor PI103, the HSP90 inhibitor 17-DMAG, or the HDAC inhibitor LBH589 plus TMZ caused marked prolongation of radiation-induced γH2AX foci formation 6 h after 6Gy irradiation. (B) Pretreatment of U251 cells with TMZ combined with PI103, 17-DMAG, or LBH589 attenuated p-DNA-PK expression.

Article Snippet: Membranes were blocked in PBS containing 0.1% Tween 20 and 5% powdered milk and probed with primary antibody directed against p-EGFR (Tyr1068), p-Akt (Ser473), p-ERK (Tyr202/204), p-p70S6K (Thr421/Ser424), HSP70, HSP90, DNA-PKs (Thr2609), Rad51, caspase-3, LC3, MMP-2, E-cadherin, and EphA2 (Cell Signaling Technology, Inc.) at 1:1000 dilutions.

Techniques: Irradiation, Control, Expressing

(Ruxolitinib + afatinib) rapidly reduces CDC37 Serine 13 phosphorylation and after 6 h CDC37 total expression . (A,B) SUM149 cells were treated with vehicle control or with (ruxolitinib + afatinib) for 2 h or for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed: (A) at 10× magnification to detect the total expression and phosphorylation levels of CDC37 and CDC37 Serine 13, respectively; (B) at 60× magnification the total expression of HSP90 and the total expression of CDC37, and the co-localization of the two proteins ( n = 3 ± SEM) * p < 0.05 greater decline than CDC37 protein expression. (C) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total expression of MCL-1 and BCL-XL ( n = 3 ± SEM) * p < 0.05 lower decline than vehicle control. (D) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 24 h. Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification ( n = 3 ± SEM) * p < 0.05 greater survival than individual expression of chaperones.

Journal: Frontiers in Oncology

Article Title: Rationally Repurposing Ruxolitinib ( Jakafi ® ) as a Solid Tumor Therapeutic

doi: 10.3389/fonc.2016.00142

Figure Lengend Snippet: (Ruxolitinib + afatinib) rapidly reduces CDC37 Serine 13 phosphorylation and after 6 h CDC37 total expression . (A,B) SUM149 cells were treated with vehicle control or with (ruxolitinib + afatinib) for 2 h or for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed: (A) at 10× magnification to detect the total expression and phosphorylation levels of CDC37 and CDC37 Serine 13, respectively; (B) at 60× magnification the total expression of HSP90 and the total expression of CDC37, and the co-localization of the two proteins ( n = 3 ± SEM) * p < 0.05 greater decline than CDC37 protein expression. (C) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed at 10× magnification to detect the total expression of MCL-1 and BCL-XL ( n = 3 ± SEM) * p < 0.05 lower decline than vehicle control. (D) SUM149 cells were transfected with empty vector control or with plasmids to express: HSP90, GRP78, HSP70, or HSP27, alone or in the indicated combinations. Twenty-four hours after transfection, cells were treated with vehicle control or with [ruxolitinib (1.0 μM) + afatinib (1.0 μM)] for 24 h. Twenty-four hours later, cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10× magnification ( n = 3 ± SEM) * p < 0.05 greater survival than individual expression of chaperones.

Article Snippet: Antibodies used include: HSP90 (E289) (Cell Signaling); HSP90 (#2928) (Abcam); HSP90 (ab195575) Abcam; HSP90 3G3 (13495) (Abcam); GRP78 (50b12) (31772) (Cell Signaling); GRP78 (ab191023) Abcam; GRP78 (ab103336) Abcam; GRP78 (N-20) (sc-1050) Santa Cruz; HSP27 (G31) (2402P) Cell Signaling); HSP27 (EP1724Y) (ab62339) Abcam; HSP27 (H-77) (sc-9012) Santa Cruz; HSP27 (LS-C31836) Lifespan science Corp. Other antibodies were as used in prior studies by the laboratory.

Techniques: Expressing, Fluorescence, Transfection, Plasmid Preparation, Live Dead Assay, Microscopy